Harvard Bioscience, Inc. is a developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, drug and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. The Company’s products and services are sold globally to customers ranging from renowned academic institutions and government laboratories to pharmaceutical, biotechnology and contract research organizations (CROs). Its two product categories are cellular and molecular technology (CMT) and Preclinical. Its CMT product family includes the Harvard Apparatus, Biochrom, BTX, HEKA, KD Scientific, MCS and Warner brands. Its Preclinical product family provides a complete platform to assess physiological data from organisms for research ranging from basic research to drug discovery, and drug development services. The Preclinical Product family includes the DSI, Panlab, Hugo Sachs and Buxco brands.
Unternehmens-codeHBIO
Name des UnternehmensHarvard Bioscience Inc
IPO-datumOct 21, 2013
Gegründet am2000
CEOMr. James W. (Jim) Green
Anzahl der mitarbeiter330
WertpapierartOrdinary Share
GeschäftsjahresendeOct 21
Addresse84 October Hill Rd
StadtHOLLISTON
BörseNASDAQ Global Market Consolidated
LandUnited States of America
Postleitzahl01746-1371
Telefon15088938999
Websitehttps://www.harvardbioscience.com/
Unternehmens-codeHBIO
IPO-datumOct 21, 2013
Gegründet am2000
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten